MX2023005864A - Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2). - Google Patents

Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2).

Info

Publication number
MX2023005864A
MX2023005864A MX2023005864A MX2023005864A MX2023005864A MX 2023005864 A MX2023005864 A MX 2023005864A MX 2023005864 A MX2023005864 A MX 2023005864A MX 2023005864 A MX2023005864 A MX 2023005864A MX 2023005864 A MX2023005864 A MX 2023005864A
Authority
MX
Mexico
Prior art keywords
targeting agent
her2
her2 targeting
fragment
antigen
Prior art date
Application number
MX2023005864A
Other languages
English (en)
Inventor
Yukinari Kato
Mika Kaneko
Daisuke Nakayama
Masayuki KUROGI
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2023005864A publication Critical patent/MX2023005864A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona: un anticuerpo o fragmento de unión al antígeno del mismo que se une a HER2 expresado en una célula cancerosa o un fragmento de HER2, un agente dirigido a HER2 que contiene cualquiera de estos, y una composición farmacéutica que contiene el agente dirigido a HER2.
MX2023005864A 2020-11-30 2021-11-29 Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2). MX2023005864A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020198044 2020-11-30
JP2021110912 2021-07-02
PCT/JP2021/043538 WO2022114163A1 (ja) 2020-11-30 2021-11-29 Ｈｅｒ２標的化剤

Publications (1)

Publication Number Publication Date
MX2023005864A true MX2023005864A (es) 2023-06-05

Family

ID=81754499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005864A MX2023005864A (es) 2020-11-30 2021-11-29 Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2).

Country Status (10)

Country Link
US (2) US20240002531A1 (es)
EP (1) EP4253420A1 (es)
JP (2) JP7393774B2 (es)
KR (1) KR20230114747A (es)
AU (1) AU2021387127A1 (es)
CA (1) CA3199473A1 (es)
IL (1) IL303154A (es)
MX (1) MX2023005864A (es)
TW (1) TW202229359A (es)
WO (1) WO2022114163A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023196994A1 (en) * 2022-04-08 2023-10-12 Fate Therapeutics, Inc. Cells having solid tumor targeting backbone and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2785941C (en) 2000-10-06 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
EP2330131B1 (en) * 2009-12-07 2014-10-08 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Antibodies against HER2 truncated variant CTF-611
WO2012047427A2 (en) * 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US11851479B2 (en) * 2018-06-18 2023-12-26 Dxdiscovery, Inc. Methods and compositions for pertussis diagnosis

Also Published As

Publication number Publication date
KR20230114747A (ko) 2023-08-01
CA3199473A1 (en) 2022-06-02
TW202229359A (zh) 2022-08-01
IL303154A (en) 2023-07-01
JP2024020436A (ja) 2024-02-14
US11981747B1 (en) 2024-05-14
US20240002531A1 (en) 2024-01-04
JPWO2022114163A1 (es) 2022-06-02
WO2022114163A1 (ja) 2022-06-02
JP7393774B2 (ja) 2023-12-07
EP4253420A1 (en) 2023-10-04
AU2021387127A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JOP20210289A1 (ar) مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها
MX2020008795A (es) Anti cuerpos anti tigit y usos de los mismos.
PH12019501330A1 (en) Antibody drug conjugates for ablating hematopoietic stem cells
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
PE20081266A1 (es) Anticuerpos e inmunoconjugados
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
WO2021227307A8 (zh) 抗cd73抗体及其用途
BR112019023909A8 (pt) Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
ZA201907225B (en) Treatment of her2 positive cancers
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
MX2022014790A (es) Receptores de antígenos quiméricos específicos de p95her2 y usos de estos.
AU2020380603A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2021012769A (es) Anticuerpos bloqueadores cd73.
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2023005864A (es) Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2).
WO2022034524A3 (en) Antibodies against ilt2 and use thereof
WO2019244082A3 (en) Antibody drug conjugates for ablating hematopoietic stem cells
MX2021008760A (es) Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
WO2023044483A8 (en) Compositions and methods for the treatment of her2 positive cancer